Page 16 - SaxoCell Annual Report 2021

Fraunhofer IZI Leipzig

The Fraunhofer Institute for Cell Therapy and Immunology IZI develops solutions to specific
problems at the interfaces of medicine, life sciences and engineering. One of our main tasks is to
conduct contract research for companies, hospitals, diagnostic laboratories and research
institutes operating in the field of biotechnology, pharmaceuticals and medical engineering. The
institute develops, optimizes and validates methods, materials and products within its business
SaxoCell Core Institutions biochemistry, bioanalytics and bioproduction as well as process development and automation.
units cell and gene therapy, drugs & vaccines, molecular diagnostics and immunodiagnostics, as
well as extracorporeal therapies. Its areas of competence lie in cell biology, immunology, drug

Research in these areas is centered around developments in immuno-oncology and infectious
disease pathology. Besides its main location in Leipzig in the Free State of Saxony, the institute
has subsidiaries in Halle, Potsdam, Rostock, Hannover and Erfurt.

In our business unit “Cell and Gene Therapy” are our technologies covering the entire early value
chain in cell and gene therapy R&D. We develop a pipeline of proprietary ATMPs (Advanced
Therapy Medicinal Products) as well as innovative platformtechnologies. In parallel, we support
development efforts of our industry partners with these technologies. Further along the
development value chain are we also offering GLP toxicology and safety studies for ATMPs and
develop reliable safety assessment strategies for ATMPs. In the ATMP manufacturing area are we
supporting our partners and internal programs with comprehensive GMP process development,
optimization and automation capabilities as well as with large scale contract manufacturing
services. We collaborate closely with the Leipzig University Hospital and thus can also support
the conduct of clinical trials.

11